Loperamide-Associated Opioid Use Disorder and Proposal of an Alternative Treatment with Buprenorphine.

: This case report describes a patient with opioid use disorder who developed cardiac toxicity secondary to non-medical use of loperamide. At recommended doses, loperamide remains in the periphery to treat diarrhea. At high doses, loperamide causes central nervous system (CNS) opioid agonism. Complications of high-dose loperamide have been documented, including cardiotoxicity, and death. This is particularly important in light of the ongoing opioid epidemic. This case presents a patient with sequela of high-dose loperamide as an illicit opioid replacement and the subsequent loperamide toxicity, including significant QTc prolongation. Abrupt cessation of his high-dose loperamide use resulted in opioid withdrawal symptoms, which were treated with buprenorphine. Buprenorphine was selected to avoid possible worsening of QTc secondary to an additional medication, such as methadone. To our knowledge, this is the first description of the use of buprenorphine for treatment of loperamide-associated opioid use disorder. Non-medical use of loperamide requires increased recognition by the health care community, including both physicians and pharmacists, because it can result in marked and life-threatening toxicity.

[1]  J. Perrone,et al.  Expanding Treatment Opportunities for Hospitalized Patients with Opioid Use Disorders. , 2017, Journal of hospital medicine.

[2]  R. Alweis,et al.  Ventricular fibrillation due to overdose of loperamide, the “poor man’s methadone” , 2017, Journal of community hospital internal medicine perspectives.

[3]  R. J. Leo,et al.  Methadone Management of Withdrawal Associated With Loperamide-related Opioid Use Disorder. , 2017, Journal of addiction medicine.

[4]  J. Melichar,et al.  Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals , 2017, Journal of psychopharmacology.

[5]  T. Szombathy,et al.  Loperamide metabolite-induced cardiomyopathy and QTc prolongation , 2017, Clinical toxicology.

[6]  R. Gerona,et al.  2015 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT) , 2015 .

[7]  G. Bigelow,et al.  QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. , 2007, Archives of internal medicine.

[8]  Timothy J. Servoss,et al.  Buprenorphine and Methadone , 2007, Journal of addictive diseases.

[9]  W. Schreiber,et al.  Buprenorphin oder Methadon im Entzug junger Opiatabhängiger , 2004 .

[10]  W. Eggleston,et al.  Loperamide Abuse Associated With Cardiac Dysrhythmia and Death. , 2017, Annals of emergency medicine.

[11]  S. Wakeman,et al.  Managing Opioid Use Disorder During and After Acute Hospitalization: A Case-Based Review Clarifying Methadone Regulation for Acute Care Settings. , 2015, Journal of addictive behaviors, therapy & rehabilitation.

[12]  R. Ali,et al.  Buprenorphine for the management of opioid withdrawal. , 2009, The Cochrane database of systematic reviews.

[13]  H. W. Clark,et al.  An open trial of low dose buprenorphine in treating methadone withdrawal. , 1994, Journal of substance abuse treatment.